EAE induction kits - Hooke Emulsion Kits™

EAE induction kits - Hooke Emulsion Kits™

 

 

 

C57BL/6 mice – immunization with MOG35-55 or MOG1-125

Cat #	Hooke Kit™	Strain	Age	Description	Size
EK-2110	MOG35-55/CFA Emulsion PTX	C57BL/6	9 to 13 weeks	Emulsion in syringes, PTX	10 mice
EK-2160	MOG1-125/CFA Emulsion PTX	C57BL/6	9 to 13 weeks	Emulsion in syringes, PTX	10 mice

 

 

 

SJL mice – immunization with PLP139-151

Cat #	Hooke Kit™	Strain	Age	Description	Size
EK-0120	[Ser140]-PLP139-151/CFA Emulsion1	SJL	8 to 9 weeks	Emulsion in syringes	10 mice
EK-2120	[Ser140]-PLP139-151/CFA Emulsion PTX	SJL	8 to 9 weeks	Emulsion in syringes, PTX	10 mice
EK-0230	PLP139-151 (native)/CFA Emulsion	SJL	8 to 9 weeks	Emulsion in syringes	10 mice

 

 

 

Lewis rats – immunization with gpMBP69-88

Cat #	Hooke Kit™	Strain	Age	Description	Size
EK-3110	gpMBP69-88/CFA Emulsion	Lewis rats	9 to 14 weeks	Emulsion in syringes	10 rats

 

 

 

Additional pertussis toxin (for use with kits above)

Cat #	Product	Description	Size	SDS (pdf)
BT-0105	Pertussis toxin in glycerol	PTX from B. pertussis in glycerol buffer	1 vial	SDS

 

 

 

Each model has advantages and disadvantages as follows:

Model	Advantages	Disadvantages
MOG35-55 in C57BL/6 mice	Well suited for study of onset and development of EAE, testing potential therapeutics. Group size can be smaller (10–12 mice/group) as EAE develops in more than 90% of mice. The first wave of EAE usually lasts 7 days, followed by partial recovery and then chronic paralysis, allowing a longer time to observe differences between experimental groups.	Poorly suited for study of EAE relapses and therapeutics targeting B cells. Antigen will not consistently induce antibody production. C57BL/6 mice mostly develop chronic EAE. Peptide-induced EAE (MOG35-55 or MBP1-11) has been reported to be independent of B cell presence. [1, 2]. Because of this, peptide-induced EAE models may not be suitable for testing therapeutics aimed at B cell depletion or impairment of B cell function.
MOG1-125 in C57BL/6 mice	Recommended for testing therapeutics aimed at impairing B cell function. Induces consistent anti-MOG1-125 antibody production. B cells have been reported as necessary for development of EAE induced by human MOG1-125. [2, 4, 5]. It is therefore likely that MOG1-125-induced EAE is a good model for testing therapeutics which target B cells.	Antigen is expensive. Spontaneous recovery is greater than when MOG35-55 is used as the antigen. Therefore the therapeutic window is smaller at the end of the study vs. use of MOG35-55.
[Ser140]- PLP139-151 in SJL mice	Well suited for study of EAE relapses. Most mice will recover from the first wave of EAE and 50 to 80% of mice will relapse. EAE incidence 90 to 100%, with synchronized EAE onset. EAE can be induced either with or without pertussis toxin (PTX).	First wave is short (2 to 5 days in most mice), followed by spontaneous recovery, resulting in a small therapeutic window at the end of the first wave of EAE. Group size of 15 to 20 is recommended for study of relapses since relapse incidence is 50 to 80%. Model lasts 40 days or longer when both first wave and relapses are followed. If PTX is administered, relapse incidence and severity will be reduced.
Native mouse PLP139-151 in SJL mice	Induces more severe EAE than [Ser140]-PLP139-151, without reducing relapse incidence (which often occurs if PTX is administered to enhance EAE severity).	Same as with [Ser140]-PLP139-151 (above). In addition, EAE can be too severe.
gpMBP69-88 in Lewis rats	Consistent disease onset and severity. Short study duration (typically 18 days).	Rats are larger than mice; require larger compound amounts. Therapeutic window is small at the end of the first wave of EAE, because rats spontaneously recover. Lewis rats do not develop demyelination and do not experience chronic phase EAE.

 

 

 

Contact & Ask

 

www.mdklab.co.kr 

MDKLAB

TEL : 02 553 0923